Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
| ▸ | EED | O75530 | 1/20 | 0.49 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 4/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29607879 | 0.88 | EED (0.59) | RENGHSREED | |
| SCHEMBL29789248 | 0.88 | EED (0.59) | RENGHSREED | |
| SCHEMBL30051514 | 0.87 | CTSC (0.57) | RENCALCRLBACE1 | |
| SCHEMBL30658577 | 0.86 | REN (0.46) | RENGHSR | |
| SCHEMBL30052854 | 0.86 | CTSC (0.56) | RENEED | |
| SCHEMBL30750436 | 0.85 | NTSR2 (0.60) | RENGHSREED | |
| SCHEMBL31026131 | 0.85 | GHSR (0.63) | RENGHSREED | |
| SCHEMBL21164378 | 0.84 | REN (0.60) | REN | |
| SCHEMBL29433973 | 0.84 | CALCRL (0.56) | RENCALCRLBACE1CTSD | |
| SCHEMBL30017540 | 0.84 | REN (0.51) | RENEEDBACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | PARP1, PARP2, PARP3 | REN 4531/4885GHSR 4870/4885EED 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.